Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s stock price reached a new 52-week low on Thursday . The stock traded as low as C$0.69 and last traded at C$0.74, with a volume of 74127 shares traded. The stock had previously closed at C$0.76.
Oncolytics Biotech Price Performance
The stock’s 50 day moving average price is C$0.99 and its 200-day moving average price is C$1.26. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The stock has a market capitalization of C$54.72 million, a PE ratio of -1.98 and a beta of 1.35.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
- Five stocks we like better than Oncolytics Biotech
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- What is the Australian Securities Exchange (ASX)
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- Health Care Stocks Explained: Why You Might Want to Invest
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
